 Terns Pharmaceuticals Inc NASDAQ: TERN reported topline results from Part 1 of Phase 1b AVIATION Trial of TERN-201 for treating patients with non-alcoholic steatohepatitis NASH. Part 1 of the AVIATION Trial met the primary safety endpoint. 